RxDoctor Payments Data

Archana Sodagam, MD

Cardiovascular Disease · Frederick, MDNPI 1487955399

Payments from drug & device makers

$3,930in general payments, 2019–2025

Across 152 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$614
  • Amgen$300
  • Novartis$291
  • Pfizer$274
  • Medtronic$263
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$87522%
  • Food & beverage$3,05578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,930 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$570,341
Medicare patients
1,859
Services billed
5,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$378,398
XareltoRivaroxaban55$66,245
EntrestoSacubitril/Valsartan35$63,775
MultaqDronedarone Hcl14$31,448
BrilintaTicagrelor33$25,412
Repatha SureclickEvolocumab18$12,259
VascepaIcosapent Ethyl12$12,080
Metoprolol Succinate429$8,573
Atorvastatin Calcium570$8,113
Colesevelam Hcl12$7,290
Dabigatran EtexilateDabigatran Etexilate Mesylate17$4,604
Ranolazine ErRanolazine47$4,281
Nifedipine ErNifedipine68$3,297
Ezetimibe72$3,118
Rosuvastatin Calcium187$2,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$274$378,398280 claims
Johnson & JohnsonXarelto$96$66,24555 claims
NovartisEntresto$291$63,77535 claims
Sanofi-aventis U.S. LLCMultaq$42$31,44814 claims
AstraZenecaBrilinta$64$25,41233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →